New Drug will Relieve Pain
Neuromax has started phase 1 CT of a novel drug AQU-005, intended for treatment of neuropathic pain of various etiology.
Preclinical trials of the drug, showing its high efficacy and positive safety profile, were completed in 2015.
Phase 1 clinical trials will help assess safety and tolerability of the drug at different dosages. Besides, other characteristics of drugs, including pharmacokinetic characteristics, will continue to be studied. It is likely, that at least 24 healthy volunteers will participate in the studies.
According to Larisa Plekhova, Medical Director of Neuromax, the new drug will be the first drug enabling positive therapeutic effects at various stages of development of pain.